<PAGE>
Registration No. 333-8149
Filed pursuant to
Rule 424(b)(3)
2,000,000 Shares
PERSEPTIVE BIOSYSTEMS, INC.
Common Stock
Par Value $.01 Per Share
_______________
This Prospectus relates to the resale of up to 2,000,000 shares (the
"Shares") of Common Stock, par value $.01 per share (the "Common Stock"), of
PerSeptive Biosystems, Inc. (the "Company") held by Millipore Corporation and
Millipore Investment Holdings Limited (the "Selling Shareholders") issuable upon
redemption of shares of the Company's Series A Redeemable Convertible Preferred
Stock, par value $.01 per share (the "Preferred Stock"). See "Selling
Shareholders." The Shares may be offered from time to time in transactions on
the Nasdaq National Market, in negotiated transactions, through the writing of
options on the Shares, or a combination of such methods of sale, at fixed prices
that may be changed, at market prices prevailing at the time of sale, at prices
related to such prevailing market prices or at negotiated prices. See "Plan of
Distribution."
The Company will not receive any of the proceeds from the sale of the
Shares. The Company has agreed to bear all expenses (other than underwriting
discounts and selling commissions, if any, and fees and expenses of counsel or
other advisors to the Selling Shareholders) in connection with the registration
and sale of the Shares being registered hereby. The Company has agreed to
indemnify the Selling Shareholders against certain liabilities, including
liabilities under the Securities Act of 1933, as amended (the "Act"), as
underwriter or otherwise.
The Company's Common Stock is quoted on the Nasdaq National Market under
the symbol "PBIO." On August 12, 1996, the last reported sale price for the
Common Stock was $8.0625 per share.
_______________
THE COMMON STOCK OFFERED HEREBY INVOLVES A HIGH DEGREE OF RISK. SEE "RISK
FACTORS" BEGINNING ON PAGE 6.
_______________
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES
AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY REPRESENTATION
TO THE CONTRARY IS A CRIMINAL OFFENSE.
_______________
The date of this Prospectus is August 12, 1996.
<PAGE>
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information filed by the Company with the Commission
pursuant to the informational requirements of the Exchange Act may be inspected
and copied at the public reference facilities maintained by the Commission at
Judiciary Plaza, Room 1024, 450 Fifth Street, N.W., Washington, D.C. 20549, and
at the following regional offices of the Commission: Seven World Trade Center,
13th Floor, New York, New York 10048 and Citicorp Center, 500 West Madison
Avenue, Suite 1400, Chicago, Illinois 60611-2511. Copies of such material can
also be obtained from the Public Reference Section of the Commission at
450 Fifth Street, N.W., Washington, D.C. 20549 at prescribed rates. The Common
Stock of the Company is traded on the Nasdaq National Market, and such reports,
proxy statements and other information may also be inspected at the offices of
The Nasdaq Stock Market, Inc., Reports Section, 1735 K Street, N.W., Washington,
D.C. 20006. This Prospectus does not contain all of the information set forth in
the Registration Statement and exhibits thereto which the Company has filed with
the Commission under the Securities Act of 1933, as amended (the "Securities
Act"), and to which reference is hereby made.
The Commission also maintains a Web site that contains reports, proxy and
information statements and other information regarding registrants that file
electronically with the Commission. The address of such site is http:
//www.sec.gov.
The Company has filed with the Commission a Registration Statement on
Form S-3 (including all amendments thereto, the "Registration Statement") under
the Securities Act with respect to the Common Stock offered hereby. This
Prospectus does not contain all of the information set forth in the Registration
Statement, certain parts of which are omitted in accordance with the rules and
regulations of the Commission. For further information regarding the Company and
the Shares offered hereby, reference is hereby made to the Registration
Statement and to the exhibits and schedules filed therewith. Statements
contained in this Prospectus regarding the contents of any agreement or other
document filed as an exhibit to the Registration Statement are not necessarily
complete, and in each instance reference is made to the copy of such agreement
filed as an exhibit to the Registration Statement, each such statement being
qualified in all respects by such reference. The Registration Statement,
including the exhibits and schedules thereto, may be inspected at the public
reference facilities maintained by the Commission at 450 Fifth Street, N.W.,
Washington, D.C. 20549 and copies of all or any part thereof may be obtained
from such office upon payment of the prescribed fees.
DOCUMENTS INCORPORATED BY REFERENCE
The following documents filed by the Company with the Commission (File No.
0-20032) are incorporated by reference herein, except as superseded or modified
herein:
1. Annual Report on Form 10-K for the year ended September 30, 1995, as
amended.
-2-
<PAGE>
2. Current Report on Form 8-K dated November 1, 1995 regarding the
definitive agreement by the Company to acquire PerSeptive Technologies II
Corporation.
3. Quarterly Report on Form 10-Q for the quarterly period ended December
31, 1995.
4. Current Report on Form 8-K dated January 9, 1996 relating to the
Company's pending lawsuit against Pharmacia Biotech, Inc., Sepracor Inc. and
BioSepra Inc.
5. Current Report on Form 8-K dated February 8, 1996 relating to the
commencement of the Company's exchange offer for all of the outstanding units of
PerSeptive Technologies II Corporation.
6. Current Report on Form 8-K dated February 29, 1996 relating to a
special meeting of the Company's stockholders at which the issuance of
securities to acquire PerSeptive Technologies II Corporation was approved.
7. Current Report on Form 8-K dated March 8, 1996 relating to the
acceptance by the Company of all outstanding units of PerSeptive Technologies II
Corporation validly tendered and not withdrawn in the Company's exchange offer
to the stockholders of PerSeptive Technologies II Corporation.
8. Quarterly Report on Form 10-Q for the quarterly period ended March 31,
1996.
9. Proxy Statement for the Company's Annual Meeting of Shareholders held
on May 6, 1996.
10. Current Report on Form 8-K dated June 28, 1996 relating to the license
of certain technology to ChemGenics Pharmaceuticals Inc. in exchange for stock
in that company.
11. The description of the Company's Common Stock, $.01 par value per
share, contained in the Registration Statement on Form 8-A filed under the
Exchange Act and declared effective on May 29, 1992, including any amendment or
reports filed for the purpose of updating such description.
12. Current Report on Form 8-K dated October 8, 1993, as amended, filed
pursuant to the Exchange Act, relating to the Company's acquisition of Vestec
Corporation.
13. Current Report on Form 8-K dated October 15, 1993, as amended, filed
pursuant to the Exchange Act, relating to the Company's acquisition of the In
Vitro Business of Advanced Magnetics, Inc.
14. Current Report on Form 8-K dated August 22, 1994, as amended, filed
pursuant to the Exchange Act, relating to the Company's acquisition of the
assets and the business of the Biosearch Division of Millipore Corporation.
-3-
<PAGE>
All documents filed by the Company pursuant to Sections 13(a), 13(c),
14 or 15(d) of the Exchange Act after the date of this Prospectus and prior to
the termination of the offering made hereby shall be deemed to be incorporated
by reference in this Prospectus and to be a part hereof from the date of filing
such documents.
Any statement contained in a document incorporated or deemed to be
incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this Prospectus to the extent that a statement contained herein
or in any other subsequently filed document which also is or is deemed to be
incorporated by reference herein modifies or supersedes such statement. Any
statement so modified or superseded shall not be deemed, except as so modified
or superseded, to constitute a part of this Prospectus.
The Company will provide without charge to each person to whom this
Prospectus is delivered, upon the written or oral request of any such person, a
copy of any document described above (other than exhibits). Requests for such
copies should be directed to Jeffrey R. Moore, Vice President-Treasury
Operations, at the principal executive offices of the Company: 500 Old
Connecticut Path, Framingham, Massachusetts 01701, telephone (508) 383-7700.
Unless the context otherwise requires, references in this Prospectus to the
"Company" or "PerSeptive" refer to PerSeptive Biosystems, Inc. and its
subsidiaries.
-4-
<PAGE>
THE COMPANY
OVERVIEW
The Company develops, manufactures and markets proprietary products and
systems for the purification, analysis and synthesis of biomolecules. The
Company's enabling products are used in the life sciences industry to reduce the
time and cost required for the development and manufacture of
biopharmaceuticals. The Company's current and planned products are based on its
patented core technologies in the fields of chromatography, immunoassay, solid-
phase synthesis, rational surface design, biological mass spectrometry and
magnetic separations.
The Company was incorporated in Massachusetts in November 1987 and was
reincorporated in Delaware in May 1989. The Company's executive offices are
located at 500 Old Connecticut Path, Framingham, Massachusetts 01701, and its
telephone number is (508)383-7700.
RECENT DEVELOPMENTS
Acquisition of PerSeptive Technologies II Corporation. In March 1996, the
Company completed its acquisition of PerSeptive Technologies II Corporation
("PTC-II"), which was organized in 1993 to accelerate research and development
of the application of the Company's core technologies to certain commercial
opportunities in large life science markets. Following the successful completion
of an exchange offer for the 2,645,000 outstanding units of PTC-II, the Company
acquired 2,603,125 of such units. The PTC-II shareholders who participated in
the exchange offer exchanged their units for 2,603,125 shares of the Company's
Common Stock and 2,603,125 new Class I Warrants to purchase the Company's Common
Stock exercisable until August 8, 1997 at an exercise price per share of $13.50.
On March 13, 1996, PTC II became a wholly owned subsidiary of the Company. Each
of the remaining 41,875 shares of callable common stock of PTC II not exchanged
in the exchange offer were automatically converted into a right to receive one
share of the Company's Common Stock. As of the date hereof, 36,475 rights were
exchanged for an equivalent number of shares of the Company's Common Stock. The
total value of the Common Stock issued in the exchange offer was approximately
$16 million based on the market value of the Common Stock on March 8, 1996. The
transaction has been accounted for as a purchase and the Company has recorded an
in-process research and development charge of approximately $6.8 million which
represents the value of acquired technologies which have not reached
commercialization.
ChemGenics Transaction. Effective as of June 28, 1996, the Company
completed a transaction with ChemGenics Pharmaceuticals Inc. ("ChemGenics")
(formerly, Myco Pharmaceuticals Inc.), in which the Company transferred certain
assets and employees of the Company's drug discovery program (acquired through
PTC-II) and entered into a non-exclusive license with ChemGenics, licensing the
Company's technology in the field of drug discovery to ChemGenics in exchange
for shares of ChemGenics' Common Stock equal to 40% of its fully diluted capital
stock, plus warrants to purchase, for a period of four years, additional shares
of Common Stock at $5.00 per share equal to 10% of such fully diluted amount.
The transaction will combine the Company's proprietary technology in the field
of drug discovery with ChemGenics' gene technologies.
-5-
<PAGE>
RISK FACTORS
In addition to the other information in this Prospectus, the following
factors should be considered carefully in evaluating the Company and its
business before acquiring the Shares offered hereby. This Prospectus contains
forward-looking statements which involve risks and uncertainties. The Company's
actual results could differ materially from those anticipated in these forward-
looking statements as a result of certain factors, including those set forth in
the following risk factors and in the Company's filings with the Commission.
Potential Downward Fluctuations in Operating Results. The Company's
operating results may vary significantly from quarter to quarter or year to
year, depending on factors such as the timing of biopharmaceutical development
and commercialization programs of the Company's customers, the timing of
increased research and development and sales and marketing expenses, the timing
and size of orders, the introduction of new products by the Company and the
capital resources of the Company's customers. The Company's current and planned
expense levels are based in part on its expectations as to future revenue.
Consequently, revenue or profits may vary significantly from quarter to quarter
or year to year and revenue or profits in any period will not necessarily be
predictive of results in subsequent periods.
Additional Financing Requirements. The Company believes additional long-
term financing will be required for the development of some of its future
planned product introductions and to support its planned operations and capital
expenditures in its core business relating to the purification, analysis and
synthesis of biomolecules. The Company is actively seeking to raise additional
capital through equity or debt financing or to enter into corporate partnering
arrangements. Such financings may result in dilution to certain existing
shareholders and there can be no assurance that capital will be available or
that terms acceptable to the Company will be reached.
History of Operating Losses and Uncertainty of Future Profitability. To
date, the Company has not achieved profitability in any fiscal year. There can
be no assurance that the Company will achieve or maintain profitability or that
its revenue growth can be sustained in the future.
SEC Investigation. In November 1994, the Commission informed the Company
that the Commission had undertaken an informal investigation related to the
Company. The Commission advised the Company in May 1995 that it had obtained a
formal order of investigation so that, among other matters, it may utilize
subpoena powers to obtain information relevant to its inquiry. The Commission
has and may in the future utilize its subpoena powers to obtain information
variously from officers, directors and employees of the Company and from persons
not presently associated with the Company. If, after completion of its
investigation, the Commission finds that violations of the federal securities
laws have occurred, the Commission has the authority to order persons to cease
and desist from committing or causing such violations and any future violations.
The Commission may also seek administrative, civil and criminal fines and
penalties and injunctive relief. The Department of Justice has the authority in
respect of criminal matters. The Company has been cooperating fully with the
Commission in its investigation. There can be no assurance as to the timeliness
of the completion of this investigation, or as to the final result thereof, and
no assurance can be given that the
-6-
<PAGE>
final result of the investigation will not have a material adverse effect on the
Company. See "Legal Proceedings."
Need to Integrate Acquisitions. In recent years, the Company has made
several acquisitions that have increased the number of the Company's employees,
the scope of its business, or both. The Company may make additional acquisitions
in the future. The success of these acquisitions will depend on a number of
factors, including the ability of the Company's management to integrate the
administrative, manufacturing and sales operations of the acquired businesses
with those of the Company, to retain key personnel of the acquired businesses,
to reduce costs and to preserve and expand the sales of the products of the
acquired businesses. There can be no assurance that the Company will be able to
successfully operate these acquired businesses or that the Company will not
experience losses as a result of these acquisitions. With respect to the
recently completed acquisition of PTC-II, the success of the combined businesses
will depend, in part, on the continued availability of funding sources for the
research and development projects of the Company and PTC-II. The Company has
recently licensed certain of the technology acquired from PTC-II to ChemGenics
in exchange for stock in that company. If other research and development
programs formerly funded by PTC-II are continued by the Company, they will be
required to be funded in total by the Company and it will be required to rely on
its own resources or seek alternative sources of capital and/or collaborative
funding. There is no assurance that sufficient sources of capital and other
funding will be available to the Company in the near term or long term to fund
all of the Company's current research and development programs and those
acquired from PTC-II.
Uncertainties Associated with Expansion of Marketing and Manufacturing
Operations. The Company intends to continue expanding rapidly its sales and
marketing efforts in the United States and other countries. The Company's
ability to accomplish this objective is dependent on many factors, including,
among others: attracting and retaining a significant number of additional sales
and marketing professionals; expanding foreign sales operations; and developing
distributor relationships in certain markets. This continued expansion will
involve significant additional expense and the risks inherent in integrating new
sales and marketing personnel into the Company's existing organization.
Increasing sales may also require expansion of the Company's manufacturing
capabilities, which would require significant capital expenditures and
management attention. There can be no assurance that the Company will be able to
accomplish its sales, marketing and manufacturing objectives.
Potential Costs Associated With Patent Litigation. Patent litigation is
widespread in the biotechnology industry and, in general, it is not possible to
predict how any such litigation would affect the Company's business. The Company
has sued two competitors for infringement of the Company's patents relating to
Perfusion Chromatography. The defendants in that suit are seeking to have these
patents declared invalid and have asserted counterclaims against the Company.
The litigation has been expanded to cover an additional patent in which the
Company has been granted rights. The Company may incur substantial additional
expenses relating to these lawsuits. There can be no assurance that the outcome
of the litigation will not have a material adverse effect on the Company. See
"Legal Proceedings."
Patent and License Uncertainties. Proprietary rights relating to the
Company's products will be protected from unauthorized use by third parties only
to the extent that they are covered by valid
-7-
<PAGE>
and enforceable patents or are maintained in confidence as trade secrets. There
can be no assurance that any pending patent applications filed by the Company
will result in patents being issued or that any patents now or hereafter owned
by the Company will afford protection against competitors. If the Company
participates in interference or other proceedings under the jurisdiction of the
U.S. Patent and Trademark Office, such proceedings could result in substantial
costs to the Company. Competitors, including those with substantially greater
resources than those of the Company, may initiate litigation to challenge the
validity of the Company's patents. Others may use their resources to design
comparable products that do not infringe the Company's patents. There may also
be pending or issued patents, of which the Company is not aware, held by parties
not affiliated with the Company that relate to the Company's products or
technology. The Company may need to acquire licenses to, or contest the validity
of, any such patents. It is likely that significant funds would be required to
contest the validity of any such patents. There can be no assurance that any
license required under any such patent would be made available on acceptable
terms or that the Company would prevail in any such contest.
Limited Protection of Trade Secrets. Certain of the technology that may be
used in the Company's products is not covered by any patent or patent
application. There also can be no assurance that the Company's non-disclosure
agreements with its employees and consultants will provide meaningful protection
for the Company's trade secrets or other proprietary information. In the absence
of patent protection, the Company's business may be adversely affected by
competitors that independently develop functionally equivalent technology.
Dependence of Customers on Government Sponsored Research. A substantial
portion of the Company's sales are to customers at universities or research
laboratories whose funding is dependent upon both the level and timing of
funding from government sources. The sensitivity of sales to uncertainties in
such funding is greatest when capital expenditures are involved, particularly
instruments at the high-price end of the Company's product offerings. As a
result, the timing and amount of revenues from these sources may vary
significantly due to factors that can be difficult to forecast.
Intense Competition and Risk of Technological Obsolescence. The Company
encounters, and expects to continue to encounter, intense competition in the
sale of its current and future products. There can be no assurance that
developments by others will not render the Company's products or technologies
obsolete or non-competitive. Many of the Company's competitors and potential
competitors have substantially greater resources, manufacturing and marketing
capabilities, research and development staff and production facilities than
those of the Company.
Government Regulation May Slow Product Introduction and Sales. The
Company's purification, analysis and synthesis products are not currently
subject to regulation by the U.S. Food and Drug Administration ("FDA"). However,
FDA regulations apply to the processes and production facilities used by the
Company's customers to manufacture biopharmaceutical products. Any material
change by a biopharmaceutical company in its manufacturing process or equipment
could necessitate additional FDA review and approval. Such requirements may make
it more difficult for the Company to sell its products to customers that have
already applied for or obtained FDA licenses for production processes using
different equipment and supplies. The Company's clinical diagnostic products are
subject to pre-marketing clearance or approval by the FDA in the United States
and by similar agencies
-8-
<PAGE>
in other countries; however the Company presently has no pending FDA clearances
or approvals. The process for obtaining such clearances and approvals can be
both lengthy and costly. There can be no assurance that necessary, timely
clearances and approvals will be granted for products developed by the Company.
Currency Exchange Risks; International Sales and Operations. The Company's
sales to customers outside of the United States account for a significant
percentage of its revenue. A substantial portion of the Company's international
sales are denominated in foreign currencies, while its costs are denominated
principally in U.S. dollars and, to a lesser extent, in Deutschmarks. Decreases
relative to the U.S. dollar in the value of currencies in which sales are made
would result in reduced sales and profit to the extent that they are not offset
by price increases. With respect to the Company's sales that are U.S. dollar-
denominated, such decreases could make their products less price-competitive.
International sales and operations may also be adversely affected by the
imposition of governmental controls, export license requirements, restrictions
on the export of critical technology, political and economic instability, trade
restrictions, changes in tariffs and taxes, difficulties in staffing and
managing international operations and general economic conditions.
Need to Attract and Retain Key Employees. The Company is highly dependent
on the principal members of its management and scientific staff. The loss of the
services of one or more of these key employees could have a material adverse
effect on the Company. The Company believes that its future success will depend
in large part upon its ability to attract and retain highly skilled scientific,
managerial and marketing personnel. Competition for such personnel is intense.
There can be no assurance that the Company will be successful in attracting or
retaining such personnel.
Risk of Product Liability Claims; Limited Insurance Coverage. The testing,
marketing and sale of biomolecule purification, analysis and synthesis products
entails an inherent risk of product liability, and there can be no assurance
that product liability claims will not be asserted against the Company.
Furthermore, there can be no assurance that the Company will continue to be able
to obtain its current limited product liability insurance coverage on reasonable
terms or that current insurance or insurance subsequently obtained will provide
adequate coverage against any or all potential claims.
Potential Adverse Effects of the Use of Hazardous Materials. Research and
development processes involve the controlled use of laboratory quantities of
hazardous materials. The Company's chemical manufacturing operations use and
dispose of significant quantities of chemicals which may be considered hazardous
under, and are subject to, applicable federal, state, local and foreign laws and
regulations governing the use, manufacture, storage, handling and disposal of
such material and certain waste products. There can be no assurance that the
Company will not be required to incur significant costs to comply with
environmental laws and regulations, nor that the operations, business or assets
of the Company will not be materially adversely affected by current or future
environmental laws or regulations.
Possible Volatility of Stock Price. From time to time there may be
significant volatility in the market price of the Company's Common Stock because
of factors unrelated, as well as related, to the Company's operating
performance.
-9-
<PAGE>
Anti-Takeover Provision; Possible Issuance of Preferred Stock. The
Company's Shareholder Rights Plan and certain provisions of the Company's
Amended and Restated Certificate of Incorporation, Amended and Restated By-Laws,
as amended, and Delaware law could discourage potential acquisition proposals
and could delay or prevent a change in control of the Company. The Company's
Amended and Restated Certificate of Incorporation and Amended and Restated By-
Laws, as amended, contain provisions that divide the Board of Directors of the
Company into three classes, so that directors are subject to re-election every
three years, that require the vote of 75% of the Company's shareholders to
remove a director without cause and that prohibit shareholder action by written
consent. The Company's Shareholder Rights Plan could diminish the opportunities
for a shareholder to participate in tender offers, including tender offers at a
price above the then current market value of the Common Stock. These provisions
may discourage acquisition bids for the Company. Such provisions could limit the
price that investors might be willing to pay in the future for shares of the
Company's Common Stock. Such provisions may also inhibit fluctuations in the
market price of the Common Stock that could result from takeover attempts. In
addition, the Board of Directors, without further shareholder approval, may
issue Preferred Stock that could have the effect of delaying, deterring or
preventing a change in control of the Company. The issuance of Preferred Stock
could also adversely affect the voting power of the holders of Common Stock,
including the loss of voting control to others. The Company is subject to the
provisions of Section 203 of the Delaware General Corporation Law. Subject to
certain exceptions, Section 203 prohibits a publicly held Delaware corporation
from engaging in a "business combination" with an "interested stockholder" for a
period of three years after the date of the transaction in which the person
became an interested stockholder, unless the interested stockholder attained
such status with the approval of the Board of Directors or unless the business
combination is approved in a prescribed manner. A "business combination"
includes mergers, asset sales and other transactions resulting in a financial
benefit to the interested stockholder. Subject to certain exceptions, an
"interested stockholder" is a person who, together with affiliates and
associates, owns, or within three years did own, 15% or more of the
corporation's voting stock. All of the foregoing provisions could have the
effect of making it more difficult for a third party to acquire, or of
discouraging a third party from acquiring, control of the Company.
No Dividends. The Company has never paid cash dividends on its Common
Stock. Payment of dividends is within the discretion of the Board of Directors
and will depend upon the Company's earnings, capital requirements, financial
condition and other relevant factors. It is the Company's intention to retain
earnings, if any, to finance the operation and expansion of its business and
therefore, it does not expect to pay any dividends on its Common Stock in the
foreseeable future.
-10-
<PAGE>
SELLING SHAREHOLDERS
The following table sets forth certain information with respect to the
Shares held by each Selling Shareholder. The Shares may be offered from time to
time by any of the Selling Shareholders. See "Plan of Distribution."
<TABLE>
<CAPTION>
Shares Beneficially
Owned Prior to Shares Shares Beneficially
Offering(1) Offered Owned After Offering (3)
----------- ------- ------------------------
Name Number Percent(2) Number Number Percent(2)
- ---- ------ ---------- ------ ------ ----------
<S> <C> <C> <C> <C> <C>
Millipore Corporation 1,346,436 7.32% 925,000 421,436 2.29%
Millipore Investment Holdings Limited 1,565,763 8.45% 1,075,000 490,763 2.65%
</TABLE>
_____________________
* Less than 1%
(1) Assumes that the Selling Shareholders will receive all of the Shares
registered hereby upon redemption of the Preferred Stock held by such Selling
Shareholders. The number of the Shares of Common Stock issuable on any
redemption date depends on the market price of the Common Stock at the time of
redemption. Consequently, the total number of the Shares of Common Stock
issuable upon redemption of the Preferred Stock, is not presently determinable.
The Company issued 421,436 shares to Millipore Corporation and 490,763 shares to
Millipore Investment Holdings Limited on August 24, 1995 upon redemption of 25%
of the Preferred Stock.
(2) The number of shares of Common Stock deemed outstanding includes (i)
17,464,697 shares of Common Stock outstanding as of August 12, 1996 and (ii)
with respect to Millipore Corporation 925,000 shares issuable upon redemption of
the Preferred Stock, and with respect to Millipore Investment Holdings Limited
1,075,000 shares issuable upon redemption of the Preferred Stock.
(3) Assumes that the Selling Shareholders will sell all of the Shares
registered hereunder. The Selling Shareholders may sell all or any part of their
Shares pursuant to this Prospectus.
Other than as described below, to the best of the Company's knowledge, none
of the Selling Shareholders had any material relationship with the Company or
any of its affiliates within the three year period ending on the date of this
Prospectus.
On August 22, 1994, the Company acquired the business and assets of the
Biosearch Division of Millipore Corporation ("Millipore"). In connection with
this acquisition, the Company paid to Millipore approximately $1,141,000 in
cash, assumed certain specified liabilities of Millipore and issued to Millipore
4,000 shares of Preferred Stock. The Preferred Stock is redeemable in four equal
-11-
<PAGE>
annual installments of 1,000 shares commencing on August 22, 1995 at a
redemption price of $10,000 per share, subject to certain adjustments, payable
at the option of the Company in cash or shares of Common Stock. The number of
shares of Common Stock issuable on any redemption date depends on the market
price of the Common Stock at the time of redemption. The Company issued 912,199
shares of Common Stock in payment of the first installment on August 24, 1995
and such shares were registered on a Registration Statement on Form S-3 filed
with the Commission on August 17, 1995. Pursuant to a registration rights
agreement among the Company and the Selling Shareholders, the Company is
registering for resale 2,000,000 shares of Common Stock that may be resold by
the Selling Shareholders upon redemption of the Preferred Stock on or before
August 22, 1998 pursuant to the registration statement of which this Prospectus
is a part. This transaction is more fully described in the Company's Current
Report on Form 8-K dated August 22, 1994, as amended, which is incorporated
herein by reference.
PLAN OF DISTRIBUTION
The Company will not receive any of the proceeds from this offering. The
Shares offered hereby may be sold from time to time by or for the account of any
of the Selling Shareholders or by their pledgees, donees, distributees or
transferees or other successors in interest to the Selling Shareholders. The
Shares may be sold hereunder directly to purchasers by the Selling Shareholders
in negotiated transactions; by or through brokers or dealers in ordinary
brokerage transactions or transactions in which the broker solicits purchasers;
block trades in which the broker or dealer will attempt to sell the Shares as
agent but may position and resell a portion of the block as principal;
transactions in which a broker or dealer purchases as principal for resale for
its own account; or through underwriters or agents. The Shares may be sold at a
fixed offering price, which may be changed, at the prevailing market price at
the time of sale, at prices related to such prevailing market price or at
negotiated prices. Any brokers, dealers, underwriters or agents may arrange for
others to participate in any such transaction and may receive compensation in
the form of discounts, commissions or concessions from the Selling Shareholders
and/or the purchasers of the Shares. Each Selling Shareholder will be
responsible for payment of any and all commissions to brokers.
The aggregate proceeds to any Selling Shareholder from the sale of the
Shares offered by the Selling Shareholder hereby will be the purchase price of
such Shares less any broker's commissions.
In order to comply with the securities laws of certain states, if
applicable, the Shares will be sold in such jurisdiction only through registered
or licensed brokers or dealers. In addition, in certain states the Shares may
not be sold unless they have been registered or qualified for sale in the
applicable state or an exemption from the registration or qualification
requirement is available and is complied with.
Any Selling Shareholder and any broker-dealer, agent or underwriter that
participate with the Selling Shareholder in the distribution of the Shares may
be deemed to be "underwriters" within the meaning of the Securities Act, in
which event any commissions received by such broker-dealers, agents or
underwriters and any profit on the resale of the Shares purchased by them may be
deemed to be underwriting commissions or discounts under the Securities Act.
-12-
<PAGE>
Under applicable rules and regulations under the Exchange Act, any person
engaged in the distribution of the Shares offered hereby may not simultaneously
engage in market making activities with respect to the Shares for a period of
two business days prior to the commencement of such distribution. In addition,
and without limiting the foregoing, each Selling Shareholder will be subject to
applicable provisions of the Exchange Act and the rules and regulations
thereunder, including, without limitation, Rules 10b-2, 10b-5, 10b-6 and 10b-7,
which provisions may limit the timing of purchases and sales of the Shares by
the Selling Shareholder.
There is no assurance that any Selling Shareholder will sell any or all of
the Shares described herein and may transfer, devise or gift such securities by
other means not described herein.
The Company will use its best efforts to cause the registration statement
to which this Prospectus relates to become effective as promptly as is
practicable and to keep the registration statement effective until two years
from the date hereof. The Company is permitted to suspend the use of this
Prospectus in connection with sales of the Shares by holders during certain
periods of time under certain circumstances relating to pending corporate
developments and public filings with the Commission and similar events. Expenses
of preparing and filing the registration statement and all post-effective
amendments will be borne by the Company.
LEGAL PROCEEDINGS
1. On October 14, 1993, the Company filed suit against Pharmacia Biotech,
Inc., a New Jersey corporation, together with certain of its affiliates, and
their parent Pharmacia AB, a Swedish corporation (collectively, "Pharmacia"),
and Sepracor Inc., a Delaware corporation ("Sepracor"), in the United States
District Court for the District of Massachusetts (Civil Action No. 93-12237-PBS)
for willful infringement of the Company's U.S. Patents Nos. 5,019,270 and
5,228,989 (collectively, the "Patents") covering the process of Perfusion
Chromatography and the manufacture, sale and use of chromatography particles
that enable Perfusion Chromatography. This lawsuit seeks to enjoin the
defendants from infringing the Patents and asks for treble damages. On October
15, 1993, the Company filed a related action against Sepracor in the United
States District Court for the District of Massachusetts (Civil Action No. 93-
12249-PBS) in which the Company claims that Sepracor has made false and
misleading representations of fact with respect to the Company's products in
violation of applicable state and federal law. On October 12, 1993, as a result
of prior correspondence with the Company, Pharmacia filed a suit against the
Company in the United States District Court for the District of New Jersey
(Civil Action No. 93-4450 (HAA)) seeking a declaratory judgment: (i) that
Pharmacia's products do not infringe the Patents and (ii) that the Patents are
invalid and unenforceable.
On January 18, 1994, the United States District Court for the District of
New Jersey allowed the Company's motion to transfer all proceedings in
Pharmacia's action to the United States District Court for the District of
Massachusetts. By orders dated December 3, 1993 and March 29, 1994, the United
States District Court for the District of Massachusetts has consolidated all
three actions identified above for pretrial proceedings.
-13-
<PAGE>
On May 19, 1994, the United States District Court for the District of
Massachusetts allowed the Company's motion to join BioSepra Inc., which is
partially owned by Sepracor ("BioSepra"), as a party and to amend the pleadings
to assert claims against BioSepra for willful infringement of the Patents and
for false and misleading advertising. The Company's claims against BioSepra are
consolidated with claims against Sepracor and Pharmacia for pretrial
proceedings.
On October 5, 1994, the Court allowed the Company's motion to amend its
pleadings to allege claims against Sepracor and BioSepra for infringement of
United States Patent No. 5,030,352 (the "'352 Patent"), covering novel coatings
for chromatography media, which is assigned to the Purdue Research Foundation
and exclusively licensed to the Company.
On January 24, 1995, the U.S. Patent and Trademark Office issued a third
patent assigned to the Company, U.S. Patent No. 5,384,042, covering the
manufacture, sale and use of matrices that enable Perfusion Chromatography. On
January 25, 1995, the Company filed a complaint in the United States District
Court for the District of Massachusetts against Pharmacia, Sepracor and BioSepra
alleging willful infringement of the '042 Patent. On February 14, 1995, the
Court allowed an assented-to motion to consolidate that action, designated Civil
Action No. 95-10157-PBS, with the pending actions described above.
Pharmacia, Sepracor and BioSepra each have asserted counterclaims against
the Company. On February 10, 1995, Sepracor and BioSepra filed a counterclaim
against the Company alleging that its allegations that Sepracor and BioSepra
have infringed the Patents and alleged statements concerning the litigation made
to customers constitute unfair competition, commercial disparagement, unfair
trade practices allegedly in violation of Mass. Gen. Laws ch. 93A, tortious
interference with customer relationships and violation of the Lanham Act.
Sepracor and BioSepra requested relief in the form of an unspecified amount of
damages, double or treble damages to the extent permitted by Mass. Gen. Laws ch.
93A, dismissal of all claims asserted by the Company, and Sepracoras costs and
attorneys' fees. On March 6, 1995, Pharmacia filed a counterclaim alleging that
the Company's allegations that Pharmacia has infringed the Patents and alleged
statements concerning the litigation made to customers constitute unfair
competition, commercial disparagement, unfair trade practices allegedly in
violation of Mass. Gen. Laws ch. 93A, and violation of the Lanham Act. Pharmacia
requested relief in the form of an unspecified amount of damages, double or
treble damages to the extent permitted by Mass. Gen. Laws ch. 93A, dismissal of
all claims asserted by PerSeptive, and Pharmacia's costs and attorneys' fees.
Since the Court has bifurcated discovery on damages issues, Sepracor and
Pharmacia have not quantified the amount of damages sought in their respective
counterclaims. The Company has denied any liability on the counterclaims.
On January 9, 1996, the Court entered an order denying the Company's motion
for partial summary judgment relating to the inventorship of the three Perfusion
Chromatography patents, and granting the Defendants' motions for partial summary
judgment that inventorship of those patents is improper for failure to name two
or more persons as joint inventors. The Court, however, affirmed the Company's
inventorship. On March 19, 1996, PerSeptive filed a Motion to Vacate the January
9 order and requested the Court to conduct an evidentiary hearing pursuant to 35
U.S.C. ((S)) 256 to determine whether the patents can and should be corrected by
adding additional alleged inventors and, among
-14-
<PAGE>
other issues, if the patents can be corrected, whether the alleged additional
inventors should be stopped from asserting any rights on account of their never
having claimed to have been inventors, among other factors. On April 29, 1996,
the court denied the Motion to Vacate. An evidentiary hearing on the
inventorship issue was conducted in May and June, 1996. Post-hearing submissions
were filed by the parties in July, 1996, and closing arguments were heard by the
Court on August 8, 1996. The Company has preserved its rights of appeal on a
number of issues, including the Court's January 9, 1996 order that inventorship
of the patents was improper for failure to name additional persons as joint
inventors.
The Company may incur substantial additional expenses relating to these
lawsuits. There can be no assurance that the outcome of the litigation will not
have a material adverse effect on the Company. The Company intends to continue
vigorously pursuing this litigation.
2. Since November 1994, the Company has been responding to informal
requests for information from the Commission relating to certain of the
Company's financial matters. In May 1995, the Company was advised by the
Commission that it had obtained a formal order of investigation so that, among
other matters, it could utilize subpoena powers to obtain information relevant
to its inquiry. The Commission has and may in the future utilize its subpoena
powers to obtain information variously from officers, directors and employees of
the Company and from persons not presently associated with the Company. If,
after completion of its investigation, the Commission finds that violations of
the federal securities laws have occurred, the Commission has the authority to
order persons to cease and desist from committing or causing such violations and
any future violations. The Commission may also seek administrative, civil and
criminal fines and penalties and injunctive relief. The Department of Justice
has the authority in respect of criminal matters. There can be no assurance as
to the timeliness of the completion of this investigation, or as to the final
result thereof, and no assurance can be given that the final result of the
investigation will not have a material adverse effect on the Company. The
Company has responded and will continue to respond to requests for information
in connection with this investigation.
LEGAL MATTERS
Certain legal matters relating to the Shares of Common Stock have been
passed upon for the Company by Testa, Hurwitz & Thibeault, LLP, Boston,
Massachusetts. Four partners of Testa, Hurwitz & Thibeault, LLP are the holders
of an aggregate of 7,734 shares of Common Stock. Two partners of Testa, Hurwitz
& Thibeault, LLP are holders of Warrants to purchase 1,000 shares of the
Company's Common Stock.
EXPERTS
The consolidated balance sheet as of September 30, 1995 and the
consolidated statements of operations, stockholders' equity and cash flows of
the Company for the year then ended, incorporated by reference in this
Prospectus, have been incorporated by reference herein in reliance on the report
of Coopers & Lybrand L.L.P., independent accountants, given on the authority of
that firm as experts in auditing and accounting.
-15-
<PAGE>
The consolidated financial statements of the Company as of and for each of
the two years in the period ended September 30, 1994 which have been
incorporated in this Prospectus by reference to the Annual Report on Form 10-K
for the year ended September 30, 1995, as amended, have been so incorporated in
reliance on the report of Price Waterhouse LLP, independent accountants, given
on the authority of said firm as experts in auditing and accounting.
The balance sheets of the Biosearch Division of Millipore Corporation as of
December 31, 1992 and 1993 and the statements of operations and cash flows for
each of the three years in the period ended December 31, 1993, incorporated by
reference in this Prospectus, have been incorporated herein in reliance on the
report, which includes an emphasis of a matter paragraph regarding allocated
costs, of Coopers & Lybrand L.L.P., independent accountants, given on the
authority of that firm as experts in accounting and auditing.
The balance sheets of the In Vitro Business of Advanced Magnetics, Inc. as
of September 30, 1993 and 1992 and the statements of operations and cash flows
for each of the three years in the period ended September 30, 1993, incorporated
by reference in this Prospectus, have been incorporated herein in reliance on
the report, which includes an emphasis of a matter paragraph regarding allocated
costs, of Coopers & Lybrand, L.L.P., independent accountants, given on the
authority of that firm as experts in accounting and auditing.
The balance sheets of Vestec Corporation as of December 31, 1992 and 1991
and the statements of operations and cash flows for each of the three years in
the period ended December 31, 1992, incorporated by reference in this
Prospectus, have been incorporated herein in reliance on the report of Mir Fox &
Rodriguez, independent accountants, given on the authority of that firm as
experts in accounting and auditing.
-16-
<PAGE>
================================================================================
No person has been authorized to give any information or to make any
representation other than those contained in this Prospectus in connection with
the offering made hereby, and if given or made, such information or
representation must not be relied upon as having been authorized by the Company
or by any other person. Neither the delivery of this Prospectus nor any sale
made hereunder shall, under any circumstances, create any implication that
information herein is correct as of any time subsequent to the date hereof. This
Prospectus does not constitute an offer to sell or a solicitation of any person
in any jurisdiction in which such offer or solicitation may not be lawfully
made.
_____________________
TABLE OF CONTENTS
<TABLE>
<CAPTION>
Page
----
<S> <C>
Available Information.................................................... 2
Documents Incorporated by Reference...................................... 2
The Company.............................................................. 5
Risk Factors............................................................. 6
Selling Shareholders..................................................... 11
Plan of Distribution..................................................... 12
Legal Proceedings........................................................ 13
Legal Matters............................................................ 15
Experts.................................................................. 15
</TABLE>
================================================================================
2,000,000 Shares
PERSEPTIVE BIOSYSTEMS,
INC.
Common Stock
__________________
PROSPECTUS
__________________
August 12, 1996
